Literature DB >> 25677280

Endophthalmitis after resident-performed intravitreal bevacizumab injection.

Khalil Ghasemi Falavarjani1, Mohammadreza Aghamirsalim2, Mehdi Modarres3, Ali Hadavandkhani2, Masih Hashemi3, Mohammad Mehdi Parvaresh3, Masood Naseripour3, Nasrollah Samiy4.   

Abstract

OBJECTIVE: To evaluate the rate of acute endophthalmitis after resident-performed intravitreal bevacizumab (IVB) injections and to compare the results with those performed by attending retina surgeons.
DESIGN: Retrospective comparative case series. PARTICIPANTS: Eight thousand thirty-seven patients treated with intravitreal injection of bevacizumab.
METHODS: A retrospective chart review of the resident-performed IVB injections at Rassoul Akram Hospital and attending-performed IVB injections at a private eye clinic between 2011 and 2014 was undertaken. Cases of clinical endophthalmitis were identified.
RESULTS: During the study interval, the overall incidence rate of postinjection endophthalmitis was 0.01% (1/8037). Antibiotic eye drops were prescribed after IVB injection for 2771 eyes (34.5%). The single case of acute endophthalmitis occurred after a resident-performed injection, and vitreous culture showed growth of Staphylococcus epidermidis. The incidence rate of acute endophthalmitis after resident-performed IVB injection was 0.02% (1/4921). No statistically significant difference was found in the rates of endophthalmitis between resident-performed and attending-performed injections (p = 1). Also, the difference in the rates of endophthalmitis between those receiving postinjection antibiotics and those who did not was not statistically significant (p = 0.3).
CONCLUSIONS: The risk for endophthalmitis after resident-performed IVB injection is low and similar to that of the supervising surgeons performing the procedure.
Copyright © 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25677280     DOI: 10.1016/j.jcjo.2014.09.005

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  5 in total

1.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

2.  Risk of Infectious Endophthalmitis From a Resident-Performed Intravitreal Injection.

Authors:  H Russell Day; Janice C Law; Jennifer L Lindsey
Journal:  J Vitreoretin Dis       Date:  2020-12-10

Review 3.  Antibiotic prophylaxis: different practice patterns within and outside the United States.

Authors:  Stephen G Schwartz; Andrzej Grzybowski; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2016-01-28

4.  Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis.

Authors:  Manuel F Bande; Raquel Mansilla; María P Pata; Maribel Fernández; María José Blanco-Teijeiro; Antonio Piñeiro; Francisco Gómez-Ulla
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

5.  Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.

Authors:  Vivek B Wani; Jamal Al-Kandari; Khalid Sabti; Faisal Aljassar; Hussain Qali; Niranjan Kumar; Anilkumar Uboweja; Khalid Al-Sabah; Fahad A Diab; Saleh Al-Rashidi
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.